Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Mepolizumab is an anti-interleukin-5 ( IL-5) monoclonal antibody that neutralizes IL-5 and
reduces eosinophil counts in both sputum and blood. Omalizumab is an anti-immunoglobulin E
(IgE) monoclonal antibody (mAb) used in the treatment of severe allergic eosinophilic asthma
The investigators propose that in patients with the dual phenotypes of severe allergic and
eosinophilic asthma, that Mepolizumab is as effective as Omalizumab. However, this trial will
also identify key clinical biomarkers that will clarify which patients will respond best to
each of these interventions.
This study will be the first direct clinical comparison of these agents and will apply expert
clinical characterization, along with cutting edge biotechnology to better inform treatment
choices for severe asthma. This is an important and urgent management problem facing the
Australian pharmaceutical scheme, where imprecision in prescribing will result in reduced
clinical effectiveness as well as substantial and sustained costs.